ICICI Securities Ltd | Retail Equity Research Revenues grew 26% YoY to | 4483 crore (I-direct estimate: | 4351 crore) mainly on account of 58% growth in the US to | 2176 crore (Idirect estimate: | 1988 crore). Strong US sales were due to Gavis consolidation and robust sales in Metformin (anti-diabetic). Domestic sales grew 12% YoY to | 991 crore (I-direct estimate: | 976 crore) EBITDA margins improved 245 bps YoY to 27.1% (I-direct estimate:...